.jpeg)
*.- “ Esta se Convierte en Nuestra Opción de SEGUNDA LÍNEA Cuando esté Disponible Para los Pacientes ” .
Es Importante Reconocer Que " la Mayoría de los Pacientes Recaen y Necesitan Terapia de SEGUNDA LÍNEA en la Progresión ", Dijo el Dr. Liu .
El ESTÁNDAR Histórico Para el Tratamiento de SEGUNDA LÍNEA Ha Sido la QUIMIOTERAPIA, Pero el Estudio DeLLphi-304 de TARLATAMAB Versus QUIMIOTERAPIA ( LURBINECTEDIN ) en Pacientes con SCLC Que Han Tenido Progresión Durante o Después de la QUIMIOTERAPIA Basada en PLATINO Ha " Redefinido esa Opción de SEGUNDA LÍNEA ", Dijo .
La Mediana de PFS Fue de 4,2 Meses en los Que Recibieron TARLATAMAB, Significativamente Más Larga Que la Mediana de PFS de 3,2 Meses en los Que Recibieron LURBINECTEDIN ( HR, 0,72; IC del 95%, 0,59-0,88; P <0,001 ) .
************
********
****
LOS AVANCES EN EL TRATAMIENTO DE SEGUNDA LÍNEA HAN SIDO LIMITADOS HASTA LA FECHA, Y EL TOPOTECAN SIGUE SIENDO EL TRATAMIENTO DE REFERENCIA , MIENTRAS QUE OTRAS OPCIONES PRESENTAN UNA EFICACIA LIMITADA Y EFECTOS SECUNDARIOS SIGNIFICATIVOS .
*************
**********
*****
LONGER SURVIVAL WITH TARLATAMAB IN SMALL-CELL LUNG CANCER .
Published by Fondazione Gianni Bonadonna at 25/08/2025 .
A PHASE 3 study shows clinical benefit for TARLATAMAB as second-line treatment after chemotherapy in patients with small-cell lung cancer .
In the PHASE III DeLLphi-304 trial recently published on The New England Journal of Medicine TARLATAMAB led to longer overall survival than chemotherapy among patients with SMALL-CELL LUNG CANCER whose disease had progressed during or after platinum-based chemotherapy.
TARLATAMAB is a bispecific T-cell engager immunotherapy that concomitantly targets delta-like ligand 3 (DLL3), which is expressed on the surface of cancer cells in 85 to 96% of patients with small-cell lung cancer, along with CD3 on T cells .
In this trial a total of 509 patients were enrolled and randomized to receive TARLATAMAB or chemotherapy (TOPOTECAN, LURBINECTEDIN, or AMRUBICIN); OVERALL SURVIVAL was longer with TARLATAMAB (median, 13,6 months) than chemotherapy (median, 8,3 months).
TARLATAMAB treatment also had a significant benefit with respect to progression-free survival and had a significant benefit over chemotherapy with respect to progression-free survival and patient-reported outcomes for dyspnea and cough, common symptoms that affect the quality of life of patients with small-cell lung cancer.
Moreover, the incidence of adverse events of grade 3 or higher was lower with tarlatamab than with chemo- therapy (54% vs. 80%), as was the incidence of adverse events resulting in treatment discontinuation (5% vs. 12%).
As authors conclude, «The DeLLphi-304 trial is a landmark study that represents an important advance in the treatment of patients with SMALL-CELL LUNG CANCER .
The results of this trial involving patients who had had a relapse underscore the importance of examining the use of TARLATAMAB in earlier lines of therapy, and such trials are ongoing .
Collectively the survival benefit, toxic effects of mainly low grade, and favorable patient-reported outcomes support the use of TARLATAMAB as treatment for SMALL-CELL LUNG CANCER that has progressed during or after initial platinum-based chemotherapy».
